Gene Therapy for Neurological Disease: State of the Art and Opportunities for Next-generation Approaches

被引:23
|
作者
Morris, Gareth [1 ]
Schorge, Stephanie [1 ,2 ]
机构
[1] UCL, Dept Neurosci Physiol & Pharmacol, London, England
[2] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England
关键词
gene therapy; inducible promoters; epilepsy; microRNA; genetic therapy; MESSENGER-RNA; MAMMALIAN-CELLS; OPEN-LABEL; EPILEPSY; EXPRESSION; VECTOR; ANTICONVULSANT; OVEREXPRESSION; PSEUDOURIDINE; THERAPEUTICS;
D O I
10.1016/j.neuroscience.2022.03.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gene therapy for rare monogenetic neurological disorders is reaching clinics and offering hope to families affected by these diseases. There is also potential for gene therapy to offer new and effective treatments for common, non-genetic disorders. Treatments for Parkinson's Disease are in clinical trials, and treatments for refractory epilepsies are due to enter first-in-human clinical trials in 2022. Gene therapies for these disorders are based on delivering genes that address the mechanism of the disease, not repairing a mutated gene. Similar 'mechanistic' gene therapies could offer treatments to a wide range of neurological and neuropsychiatric diseases where there is a known mechanism that could be restored using gene therapy. However, the permanent nature of most gene therapies is a serious drawback for translation of gene therapies to a wide-range of diseases because it could present risk of irreversible adverse effects. Several lines of research are aimed at developing gene therapy approaches that allow for the treatment to be turned on and off, including: using proteins activated by exogenous ligands, and promoters turned on by activators. We review these approaches and propose an overall de-risking strategy for gene therapy for common neurological and psychiatric diseases. This approach is based on using a temporary mRNA-based treatment to initially assess efficacy and safety of the planned manipulation, and only following with permanent, virally-delivered treatment if the approach appears safe and effective. (c) 2022 Published by Elsevier Ltd on behalf of IBRO.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 50 条
  • [21] Next-Generation Sequencing in Blood Group Genomics: State of the Art and Perspectives
    Gassner, Christoph
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2020, 47 (01) : 2 - 3
  • [22] Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy
    Zeballos, C. M. Alejandra
    Gaj, Thomas
    TRENDS IN BIOTECHNOLOGY, 2021, 39 (07) : 692 - 705
  • [23] Next-generation CML therapy
    Victoria Aranda
    Nature Medicine, 2013, 19 (1) : 28 - 28
  • [25] HUMAN DISEASE Next-generation sequencing of the next generation
    Burgess, Darren J.
    NATURE REVIEWS GENETICS, 2011, 12 (02) : 78 - 79
  • [26] Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson′s Disease
    Pillay, Nikita Simone
    Ross, Owen A.
    Christoffels, Alan
    Bardien, Soraya
    FRONTIERS IN GENETICS, 2022, 13
  • [27] Challenges and opportunities in next-generation cyberspace security
    Park, Jong Hyuk
    Gritzalis, Stefanos
    Cheng, Bo-Chao
    Zhang, Ning
    SECURITY AND COMMUNICATION NETWORKS, 2016, 9 (06) : 455 - 456
  • [28] Challenges and Opportunities for Next-Generation Manufacturing in Space
    Nieman, Kip
    Leonard, A. F.
    Tyrrell, Katie
    Messina, Dominic
    Lopez, Rebecca
    Durand, Helen
    IFAC PAPERSONLINE, 2022, 55 (07): : 963 - 968
  • [29] Next-generation influenza vaccines: opportunities and challenges
    Chih-Jen Wei
    Michelle C. Crank
    John Shiver
    Barney S. Graham
    John R. Mascola
    Gary J. Nabel
    Nature Reviews Drug Discovery, 2020, 19 : 239 - 252
  • [30] OPPORTUNITIES FOR THE NEXT-GENERATION OF CHEMICAL-ENGINEERS
    BEGITT, K
    CHEMIE INGENIEUR TECHNIK, 1995, 67 (08) : 920 - 921